Our data provide a likely explanation as to why loss of Casp8 and low levels of Ripk1 can be driver mutations in certain types of cancer, leading to chromosome instability that may favor tumor evolution, heterogeneity, acquisition of drug resistance, and heightened risk for tumor relapse. This evidence concerns the gene RIPK1 and neoplasm.